BioVie Inc

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Earnings data Q1 2025

Earnings data Q4 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

BioVie, Inc. is a biopharmaceutical company, which engages in discovery, development, and marketing drug therapies for neurological and neurodegenerative disorders and liver disease. The company was founded on April 10, 2013 and is headquartered in Carson City, NV.

Thursday, November 11th @ 1:00pm ET Thursday, November 11th @ 1:00pm ET

BioVie Hosting Key Opinion Leader Webinar on Complications of Advanced Liver Cirrhosis and BIV201 Phase 2b Clinical Trial Update

Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Oversee Development Programs in Neurodegenerative and Liver Disease Dr. Joseph M. Palumbo, Distinguished Pharma Industry Veteran, to Oversee Development Programs in Neurodegenerative and Liver Disease

BioVie Announces the Appointment of a New Chief Medical Officer

The FDA has signed off BioVie Inc's (NASDAQ: BIVI) Phase 2 study assessing NE3107's potential pro-motoric impact in Parkinson's disease patients. The NM201 study is a double-blind, placebo-controlled, safety, tolerability, and pharmacokinetics study in Parkinson's disease (PD) participants treated with carbidopa/levodopa and NE3107.

Why Did BioVie Shares Jump 21% Today?

SANTA MONICA, Calif., Oct. 26, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that the FDA has authorized the company to initiate a Phase 2 study assessing NE3107's potential pro-motoric impact in Parkinson's disease patients.

BioVie Announces FDA Authorization to Initiate Phase 2 Trials Assessing NE3107's Pro-motoric Activity in Parkinson's Disease

SANTA MONICA, Calif., Oct. 13, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) (“BioVie” or the “Company”), a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced that it will host a key opinion leader (KOL) webinar on neuroinflammation and insulin resistance and new treatment approaches for Alzheimer's Disease on Tuesday, October 26, 2021 at 1:30 pm Eastern Time.

BioVie Hosting Key Opinion Leader Webinar on Neuroinflammation and Insulin Resistance and New Treatment Approaches for Alzheimer's Disease

SANTA MONICA, Calif., Sept. 22, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders and advanced liver disease, today announced the participation of its management team at the Cantor Virtual Global Healthcare Conference to be held September 27-30, 2021.

BioVie to Present at Cantor Virtual Global Healthcare Conference

SANTA MONICA, Calif., Sept. 15, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurodegenerative disorders and advanced liver disease, today announced the participation of its management team in the Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit September 22, 2021.

BioVie to Present at Oppenheimer Fall Healthcare Life Sciences & MedTech Virtual Summit

SANTA MONICA, Calif., Aug. 11, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the closing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of $8.00 per share, for gross proceeds of $20,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45 day option to purchase up to an additional 375,000 shares of common stock to cover over-allotments at the offering price, less the underwriting discount.

BioVie Inc. Announces Closing of Public Offering of Common Stock

BioVie Inc (NASDAQ: BIVI) priced its underwritten public offering of 2.5 million shares at $8.00 per share for gross proceeds of $20 million. The offer price represents a steep discount of 37.7% from the last close price of $12.85 on Friday.

BioVie Stock Plunges On $20M Capital Raise Via Equity At Deep Discount Of 38%

SANTA MONICA, Calif., Aug. 08, 2021 (GLOBE NEWSWIRE) -- BioVie Inc., (NASDAQ: BIVI) (“BioVie” or the “Company”) a clinical-stage company developing innovative drug therapies for the treatment of neurological and neurodegenerative disorders, liver disease and certain cancers, today announced the pricing of its underwritten public offering of 2,500,000 shares of its Class A common stock at a public offering price of $8.00 per share, for gross proceeds of  $20,000,000, before deducting underwriting discounts, commissions and offering expenses. In addition, the Company has granted the underwriters a 45 day option to purchase up to an additional 375,000 shares of common stock to cover over-allotments at the offering price, less the underwriting discount.

BioVie Inc. Announces Pricing of Public Offering of Common Stock

Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021 Pivotal Phase 3 Trial of NE3107 Expected to Commence in Summer 2021

Basis for BioVie's Phase 3 Clinical Trial of NE3107 in the Treatment of Alzheimer's Disease Published in Neurodegenerative Disease Management

NE3107 Featured in the ADA's Thought Leadership Film Series at Annual Scientific Session NE3107 Featured in the ADA's Thought Leadership Film Series at Annual Scientific Session

Development of BioVie's NE3107 Asset Featured by the American Diabetes Association

SANTA MONICA, Calif., June 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today announced has been added as a member of the broad-market Russell Microcap Index, effective after the US market opens on June 28, as part of the 2021 Russell indexes reconstitution.

BioVie Added to Russell Microcap® Index

Chairman Terren Peizer discusses BioVie's late-stage drug pipeline with multiple shots on goal Chairman Terren Peizer discusses BioVie's late-stage drug pipeline with multiple shots on goal

BioVie Interview to Air on Bloomberg Television U.S. on the RedChip Money Report®

SANTA MONICA, Calif., May 12, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and neurological and neuro-degenerative disorders and certain cancers, today announced that it will host a research and development day on Wednesday, May 19, 2021 from 12:00pm – 2:00pm Eastern Time.

BioVie Hosting Research & Development Day

BioVie (BIVI) could be a stock to avoid from a technical perspective, as the firm is seeing unfavorable trends on the moving average crossover front

Moving Average Crossover Alert: BioVie (BIVI)

SANTA MONICA, Calif., May 10, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for chronic debilitating liver diseases, today announced amendments to certain terms for the previously announced acquisition of the biopharmaceutical assets of NeurMedix, Inc., (NeurMedix), a San Diego based privately held clinical-stage pharmaceutical company focused on novel therapeutic assets for the treatment of neurodegenerative and neurological disorders, as well as certain cancers.   The pivotal Phase 3 trial in Alzheimer's Disease is expected to begin this summer.

BioVie Announces Amended Terms for Asset Acquisition from Privately Held NeurMedix

SANTA MONICA, Calif., April 28, 2021 (GLOBE NEWSWIRE) -- BioVie Inc. (NASDAQ: BIVI) ("BioVie" or "Company"), a clinical-stage company developing innovative drug therapies for the treatment of liver disease and, pending closing of the announced transaction with NeurMedix, neurological and neuro-degenerative disorders and certain cancers, today announced the participation of its President and Chief Executive Officer Cuong Do at the 2021 B. Riley Securities' Neuroscience Conference. Mr. Do is scheduled to present on Wednesday, April 28 at 3:00 PM Eastern Time and will discuss BioVie's pending acquisition of NeurMedix's assets and plans going forward for Alzheimer's and Parkinson's.

BioVie to Present at 2021 B. Riley Securities' Neuroscience Conference

News for BioVie Inc Stock (BIVI)